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Dendritic cells (DCs) are professional antigen-presenting 
cells that sample their environment and present antigens to 
naïve T lymphocytes for the subsequent antigen-specific 
immune responses. DCs exist in a range of distinct sub-
populations including plasmacytoid DCs (pDCs) and clas-
sical DCs (cDCs), with the latter consisting of the cDC1 
and cDC2 lineages. Although the roles of DC-specific 
transcription factors across the DC subsets have become 
understood, the posttranscriptional mechanisms that regu-
late DC development are yet to be elucidated. MicroRNAs 
(miRNAs) are pivotal posttranscriptional regulators of 
gene expression in a myriad of biological processes, but 
their contribution to the immune system is just beginning 
to surface. In this study, our in-house probe collection was 
screened to identify miRNAs possibly involved in DC de-
velopment and function by targeting the transcripts of rele-
vant mouse transcription factors. Examination of DC sub-
sets from the culture of mouse bone marrow with Flt3 li-
gand identified high expression of miR-124 which was 
able to target the transcript of TCF4, a transcription factor 
critical for the development and homeostasis of pDCs. 
Further expression profiling of mouse DC subsets isolated 
from in vitro culture as well as via ex vivo purification 
demonstrated that miR-124 was outstandingly expressed in 
CD24
＋
 cDC1 cells compared to in pDCs and CD172α
＋
 
cDC2 cells. These results imply that miR-124 is likely in-
volved in the processes of DC subset development by post-
transcriptional regulation of a transcription factor(s).
[Immune Network 2016;16(1):61-74]
Keywords: Dendritic cells, MicroRNAs, Posttranscriptional 
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INTRODUCTION
Dendritic cells (DCs) are antigen-presenting cells found in 
lymphoid as well as non-lymphoid tissues and organs. 
They principally act as specialized sentinel cells that sam-
ple their local environment for antigens, migrate to lymph 
nodes, and present antigens to naïve T lymphocytes, which 
is essential for the subsequent antigen-specific T-cell acti-
vation and induction of immune responses (1). Many vari-
eties of DCs have been described in both humans and mice 
with each characterized by particular locations, phenotypic 
morphologies, and functions. In essence, DCs consist of 
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a range of functionally distinct subsets that can be identi-
fied by their differential expression of particular surface 
markers (1,2). The DC subsets prevalent in lymphoid tis-
sues include antigen-presenting classical DCs (cDCs) and 
type 1 interferon-producing plasmacytoid DCs (pDCs). 
The lymphoid tissue-resident cDCs are further divided into 
different subtypes including CD8α
＋
CD24
＋
 cDCs (cDC1), 
which efficiently cross-present antigens to CD8
＋
 T cells 
and principally produce IL-12; and CD8α
−
CD172α
＋
 
cDCs (cDC2), which present MHC Class II restricted anti-
gens to CD4
＋
 T cells. Also, more DC subtypes develop 
upon infection or inflammation such as the monocyte-de-
rived inflammatory DCs.
  The development of DCs to their respective subset coun-
terparts arise through a multistage process. Like all other 
immune cells, DCs develop from hematopoietic stem cells 
in the bone marrow (BM). Hematopoietic stem cells differ-
entiate into the myeloid progenitors, which subsequently 
differentiate into the macrophage-DC progenitor (MDP) 
cells and then into the common-DC progenitor (CDP) cells 
(3). CDPs develop into pre-DCs and then egress from the 
BM to the periphery, which seed peripheral secondary 
lymphoid tissues and non-hematopoietic tissues and ulti-
mately mature into either cDCs or pDCs. Development of 
DC subsets from their progenitor cells can be replicated 
in vitro with various culture conditions. Culture of DC pro-
genitors in BM with the growth factor Flt3 ligand (Flt3L) 
produces a heterogeneous population containing both cDCs 
and pDCs, which are equivalent to their in situ counter-
parts with respect to cell surface marker expression, tran-
scription factor reliance, cytokine production, receptor 
molecule expression, and antigen-presenting ability to T 
cells (4,5). Principally, DC subsets originated from Flt3L- 
cultured BM cells correspond to those of steady-state cDC 
populations. Beyond these mature DC subsets, relevant 
progenitor and precursor populations can also be identified 
and isolated from BM cells in steady state as well in cul-
ture with Flt3L (6,7). 
  In light of these investigatory advances, the roles of 
transcription factors in DC development and their dynamic 
profiles across the subsets have become well understood 
(8-10). For example, the transcription factor PU.1 has been 
described to play a role in the development of all DCs. 
Meanwhile, STAT5 is known to drive the development of 
cDCs over pDCs through the inhibition of transcription 
factor interferon regulatory factor 8 (Irf8), whereas im-
munoglobin transcription factor 2 (TCF4) is known to 
drive pDC development over cDCs by directly activating 
Irf8 and other pro-pDC transcription factors such as SpiB 
(9-11). As such, a comprehensive group of transcription 
factors and their involvement in the particular stages of 
DC development have been mapped. In contrast to these 
transcriptional mechanisms, posttranscriptional mechanisms 
that regulate DC development are less well understood. 
With the heterogeneity of subsets and wide-ranging func-
tion of DCs, the natural question arises on how DC differ-
entiation and development is regulated besides the orches-
tration of growth factors and transcription factors. Recently, 
increasing evidence has shown that microRNAs (miRNAs) 
play an important role in fine-tuning DC development and 
function.
  miRNAs are an evolutionarily conserved class of short, 
endogenous, non-coding RNAs about 19∼23 nucleotides 
long that regulate protein synthesis by targeting the com-
plementary 3’ untranslated region (UTR) of mRNAs for 
translational repression and degradation (12). miRNA bio-
genesis begins with the transcription of a miRNA gene to 
generate a primary miRNA (pri-miRNA) transcript, which 
is ultimately processed into a mature 19∼23 bp miRNA 
and incorporated into an RNA-induced silencing complex 
(13) for the translational repression or degradation of tar-
get mRNAs. A key characteristic of miRNAs is that each 
has the ability to inhibit a myriad of mRNAs, and each 
mRNA can be targeted by many miRNAs. This is sugges-
tive of a complex network of miRNAs surrounding DC 
development. 
  miRNAs have been shown to be vital in controlling 
many processes within the immune system. Their involve-
ment in regulating T- and B-lymphocyte development has 
been established of late and their wide-ranging roles in cell 
differentiation, homeostasis, cytokine responses, and inter-
actions with pathogens and tolerance induction among oth-
ers have been described (14). More recent progressions 
have attempted to describe the role of miRNAs in DC de-
velopment (15). Several miRNAs have been specifically 
attributed to the direct regulation of certain DC functions. 
More have been identified by the comprehensive mapping 
of dynamic miRNA profiles across the subsets and tested 
to confirm their necessity in DC lineage commitment 
(15-21). In the present study, to identify miRNAs possibly 
involved in DC development and function, we screened for 
the expression of candidate miRNAs that target the 3’UTR 
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of relevant transcriptional factors using our in-house probe 
collection. Our screening results indicated that miR-124, 
able to target the 3’UTR of TCF4 transcript, was highly 
detected in mouse DC subsets. Further expression profiling 
of mouse DC subsets demonstrated that miR-124 was out-
standingly expressed in CD24
＋
 cDC1 cells compared to 
in pDCs and CD172α
＋
 cDC2 cells. Our findings imply 
that miR-124 is likely involved in the processes of DC 
subset development by posttranscriptional regulation of a 
transcription factor(s). 
MATERIALS AND METHODS
Animals 
Mice were maintained and bred in specific pathogen-free 
facilities of the Department of Laboratory Animal Resources 
at the Yonsei University College of Medicine. C57BL/6 
mice were purchased from Jackson Laboratory (Bar Harbor, 
ME, USA) and Orient Bio (Seongnam, Republic of Korea). 
Animal care and experiments were conducted according to 
the guidelines and protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of Yonsei 
University College of Medicine. Only healthy male mice 
at 6 to 12 weeks of age were used throughout this study. 
Cells, antibodies, and reagents 
Chinese hamster ovary (CHO) cells (CHO-S cells; Gibco, 
Life Technologies, Carlsbad, CA, USA) were cultured in 
DMC7 medium composed of DMEM containing L-gluta-
mine, high glucose, and pyruvate (HyClone, Logan, UT, 
USA) and 7% fetal calf serum (FCS; HyClone) supple-
mented with 1× solutions of non-essential amino acids and 
antibiotic-antimycotic (HyClone). The following conjugated 
antibodies were purchased from BioLegend (San Diego, CA, 
USA): APC-Cy
TM
7-conjugated anti-I-A/I-E, anti-CD11c, 
anti-B220/CD45R, anti-CD45, anti-Rat IgG2b κ Isotype Con-
trol; Alexa Fluor
Ⓡ
 647-conjugated anti-CD117; APC-con-
jugated anti-B220/ CD45R, anti-PDCA-1 (BST2, CD317), 
anti-CD135; PE- Cy
TM
7-conjugated anti-Ly6G, anti-CD3, 
anti-CD11c, anti-CD19, anti-Ter119, anti-DX5, anti-I-A/I-E, 
anti-NK1.1, anti-Gr-1, anti-Sca-1; PerCP-Cy
TM
5.5- con-
jugated anti-Ly6C, anti-CD11c, anti-CD24, anti-CD117, an-
ti-CD172α (Sirpα); PE-conjugated anti-SiglecH, anti- 
CD11c, anti-CD115, anti-CD117, anti-CD135, anti-Arme-
nian Hamster (AH) IgG Isotype Control; FITC-conjugated 
anti-CD172α; Alexa Fluor
Ⓡ
 488-conjugated anti-Ly6C, an-
ti-CD172α, anti- PDCA-1, anti-CD24, anti-CD45.2; Bril-
liant Violet
TM
 421 (BV421)-conjugated anti-CD11c, an-
ti-CD45.1, anti-CD45.2, anti-CD115, anti-AH IgG Isotype 
Control; biotin-conjugated anti-NK1.1, anti-DX5, anti 
Ter119, anti-Ly6G, anti-CD3, anti-CD19, anti-CD135. LIVE/ 
DEAD
Ⓡ
 fixable dead cell stain kit (Life Technologies) and 
propidium iodide (Roche, Indianapolis, IN, USA) were pur-
chased and used according to the manufacturers’ ins-
tructions.
Production of mouse Flt3L from CHO cells
The cDNA of mouse Flt3L was cloned by RT-PCR of total 
splenic RNA from C57BL/6 mice, and was used to gen-
erate a construct encoding soluble FLAG and OLLAS tag-
ged Flt3L, internal ribosomal entry site (IRES), and en-
hanced green fluorescence protein (EGFP), i.e., SFO.Flt3L- 
IRES-EGFP. The GenBank accession number for the se-
quence including the extracellular domain of mouse Flt3L 
is GU168042, and the IRES-EGFP sequence is from 
pIRES-EGFP plasmid (Clontech, Mountain View, CA, 
USA). CHO cells were then transfected using Lipofect-
amine 2000 (Life Technologies), with a mammalian ex-
pression vector plasmid encoding SFO.Flt3L-IRES-EGFP 
under CMV promoter and a neomycin resistance gene, 
constructed with the backbone of pEGFP-N1 (Clontech). 
CHO/Flt3L cells stably expressing the SFO.Flt3L-IRES- 
EGFP were produced by the following steps: (i) treatment 
of transfected CHO cells with G418 (1.5 mg/ml) for 1 
week; (ii) enrichment of EGFP-positive CHO cells with 
FACSAria II cell sorter (BD Biosciences, San Diego, CA, 
USA); (iii) generation of clonal cells by limiting dilutions 
of FACS-sorted EGFP- high CHO/Flt3L cells; and (iv) se-
lection of CHO/Flt3L clones after evaluating both levels 
of EGFP expression by FACS analysis and Flt3L secretion 
by anti-OLLAS Western blot analysis (22). Chosen 
CHO/Flt3L cells were cultured in cell culture flasks with 
DMC7 to produce CHO/ Flt3L-conditioned medium.
Western blot analysis
Different amounts of supernatant from CHO/Flt3L cell cul-
ture were mixed with an equal volume of 2×SDS PAGE 
sample buffer and boiled at 95
o
C for 5 min. The samples 
were then separated in 12% SDS-PAGE and transferred 
onto PVDF membranes (Thermo Fisher Scientific, Rock-
ford, IL, USA) before being incubated with anti-OLLAS 
monoclonal antibody (22). Anti-OLLAS antibody-reactive 
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bands on the blots were examined after incubation with 
peroxidase-conjugated anti-rat IgG antibody (Southern-
Biotech, Birmingham, AL, USA) and subsequent visual-
ization with SuperSignal
TM
 West Pico Chemiluminescent 
Substrate (Thermo Fisher Scientific) and ImageQuant
TM
 
LAS 4000 mini (GE Healthcare Life Sciences, Pittsburgh, 
PA, USA). Graded quantities (0∼160 ng) of purified 
OLLAS-tagged Gag p41 protein (2) were evaluated in par-
allel for quantification of OLLAS-tagged Flt3L bands. 
Preparation and culture of primary cells
Mice were sacrificed by asphyxiation in a CO2 chamber. 
Whole splenocyte suspension was prepared by cutting and 
mincing extracted spleens followed by grinding with frosted 
glasses and cell strainers (BD Biosciences). Whole BM cell 
suspension was prepared by flushing out femurs and tibias 
excised from the hind legs of mice in sterile conditions 
as described previously (23). Then, the single cell suspen-
sion was cultured in either 48- or 24-well tissue culture 
plates at 1⨯10
6
 or 2⨯10
6
 cells per well, respectively, with 
DMC7 containing different doses of Flt3L, i.e., CHO/Flt3L 
conditioned medium described above. During the culture, 
half of the medium in each well was carefully removed 
and replenished with fresh DMC7 containing Flt3L every 
2 days until harvest for use in subsequent experiments. 
Flow cytometry
Single cell suspensions from the harvest of mouse organ 
tissues or cultures thereof were incubated with 2.4G2 (Fc 
blocker) hybridoma supernatant and washed with FACS 
buffer (2% FCS, 2 mM EDTA, 0.1% sodium azide). Then, 
each sample was incubated with the appropriate mixture 
of fluorochrome-conjugated monoclonal antibodies and 
live/dead staining dye for 30 min at 4
o
C and washed twice 
with FACS buffer. The samples were then analyzed with 
FACSVerse flow cytometer (BD Biosciences) or sorting 
with FACSAria II cell sorter (BD Biosciences). As for sort-
ing, the isolated cells with 90% or higher purity were uti-
lized for subsequent experiments. Gating criteria for re-
spective precursor and DC populations were as follows. 
With the lineage (Lin) markers of CD3, CD19, Ly6G, 
NK1.1, DX5, Ter119: for pDCs, Lin
−
CD11c
＋
B220
＋
PDCA-1
＋
SiglecH
＋
; for cDC1, Lin
−
CD11c
＋
MHCII
＋
B220
−
CD24
high
CD172α
−
; for cDC2, Lin
−
CD11c
＋
MHCII
＋
B220
−
CD24
int
CD172α
＋
. With the lineage markers of CD3, 
CD19, Ly6G, NK1.1, DX5, Ter119, MHCII, B220: for 
MDP, Lin
−
CD11c
−
CD115
＋
CD135
＋
CD117
high
; for CDP, 
Lin
−
CD11c
−
CD115
＋
CD135
＋
CD117
int
. Flow cytometric 
data were analyzed using FlowJo software (FlowJo, Ash-
land, OR, USA).
Isolation of RNA
Total RNA was isolated from sorted cells from cultured 
or uncultured mouse primary cells using TRIzol
Ⓡ
 Reagent 
(Life Technologies) following the manufacturer’s instruc-
tions.
Real-time RT-PCR of miRNA
For miRNA expression profiling, 100 ng of purified total 
RNA was used for reverse transcription using Taqman
Ⓡ
 
MicroRNA Reverse Transcriptase Kit (Applied Biosys-
tems, Foster City, CA, USA). The resultant cDNA was used 
in combination with Taqman
Ⓡ
 MicroRNA Assays (Applied 
Biosystems) for respective miRNA and U6 control tran-
scripts and Taqman
Ⓡ
 Universal Master Mix II (Applied 
Biosystems) for PCR according to the manufacturer’s 
instructions. The amplification and detection of products 
were performed in a Light Cycler 480 II (Roche) with an 
initial denaturation at 95
o
C for 10 min, followed by 40∼60 
cycles of amplification at 95
o
C for 15 sec and 60
o
C for 
60 sec, before cooling. The threshold cycle (Ct) of miR-124 
expression was automatically defined, located in the linear 
amplification phase of the PCR, and normalized to the con-
trol U6 (ΔCt value). The relative difference in expression 
levels of miR-124 in the sorted cells (ΔΔCt) was calcu-
lated and presented as the fold induction (2
−ΔΔCt
). 
Real-time RT-PCR of transcription factors and pri- 
miR-124
For pri-miR-124 profiling, 100 ng of purified total RNA 
was used for reverse transcription using PrimeScript
TM
 RT 
Reagent Kit (TaKaRa Bio Inc., Ohtsu, Japan). The re-
sultant cDNA was used in combination with primer oligo-
nucleotides designed for DC-related transcription factors 
(5) and pri-mmu-miR-124-1/-2/-3 (24) and SYBR
Ⓡ
 Pre-
mix Ex Taq II (TaKaRa) for PCR according to the manu-
facturer’s instructions. Sequences for the primer oligonu-
cleotides, synthesized by Cosmo Genetech (Seoul, Korea), 
are as follows: TCF4, 5’-TGAGATCAAATCCGACGA-3’ 
forward, 5’-CGTTATTGCTAGATCTTGACCT-3’ reverse; 
Batf3, 5’-AGACCCAGAAGGCTGACAA-3’ forward, 5’- 
CTGCACAAAGTTCATAGGACAC-3’ reverse; Irf8, 5’- 
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AAGGGCGTGTTCGTGAAG-3’ forward, 5’-GGTGGCG 
TAGAATTGCTG-3’ reverse; pri-miR-124-1, 5’-GCCTCT 
CTCTCCGTGT-3’ forward, 5’-CCATTCTTGGCATTCA- 
3’ reverse; pri-miR-124-2, 5’-AGAGACTCTGCTCTCCG 
TGT-3’ forward, 5’-CTCCGCTCTTGGCATTC-3’ reverse; 
pri-miR-124-3, 5’-GGCTGCGTGTTCACAG-3’ forward, 
5’-ATCCCGCGTGCCTTA-3’ reverse; GAPDH, 5’-ACA 
GTCCATGCCATCACTGCC-3’ forward, 5’-GCCTGCTT 
CACCACCTTCTTG-3’ reverse. The amplification and de-
tection of products were performed in a Light Cycler 480 
II (Roche) with an initial denaturation at 95
o
C for 5 min, 
followed by 40∼60 cycles of PCR at 95
o
C for 5 sec and 
50
o
C for 30 sec, before melting and cooling. The relative 
difference in expression levels for pri-miR-124-1/-2/-3 in 
the sorted cells was calculated and presented as described 
above but with normalization to the control GAPDH. 
Luciferase activity assay
The predicted target genes of miR-124 were identified us-
ing a public database (miRWalk2.0, http://www.umm.uni- 
heidelberg.de/apps/zmf/mirwalk). Sections containing the 
miR-124 binding site of the 3’UTR of TCF4 and Zbtb46 
were cloned into pmirGLO Dual-Luciferase miRNA Target 
Expression Vector (Promega, Fitchburg, WI, USA) in-
dependently. HeLa cells were seeded at 2.5×10
4
 cells per 
well in a 24-well plate. After 48 hrs, the pmirGLO vector 
containing the target mRNA binding site for the miR-124 
was co-transfected with mmu-miR-124 mimic (Applied 
Biosystems) or the negative control using Lipofectamine 
2000 (Life Technologies). Luciferase activity was meas-
ured after 48 hrs using Dual Luciferase Assay System 
(Promega) according to the manufacturer’s instructions on 
a luminometer (Promega). Renilla luciferase activity was 
used to normalize the transfection efficiency. Each assay 
was repeated at least 3 times.
Statistical analysis
Experiments with multiplicated samples were presented as 
mean±SEM from at least three independent experiments. 
Statistical comparisons between different groups were ana-
lyzed using unpaired Student’s t-test using SigmaPlot (Systat 
Software, San Jose, CA). Statistical significance is denoted 
by the p values equal or below 0.05 (*), 0.01 (**), and 
0.001 (***). Data were plotted for graphs with SigmaPlot. 
RESULTS
Production of Flt3L and culture of bone marrow
We generated the extracellular domain sequence of mouse 
Flt3L fused with the sequences of signal peptide, FLAG 
tag, and OLLAS tag. This soluble FLAG and OLLAS tag-
ged Flt3L (SFO.Flt3L) sequence was devised to express 
with IRES and EGFP under CMV promoter (Fig. 1A) fol-
lowing transfection into CHO cells. CHO cells expressing 
high levels of Flt3L were enriched by sorting for EGFP, 
cloned, and named CHO/Flt3L cells (Fig. 1B). The con-
ditioned medium from CHO/Flt3L cells was produced in 
large volume, sterilized by filtration, and blotted with an-
ti-OLLAS antibody for the determination of Flt3L concen-
tration before being added into the culture of BM cells. 
According to the anti-OLLAS Western blot analysis, the 
CHO/Flt3L conditioned medium was evaluated to contain 
approximately 10 μg/ml of Flt3L (Fig. 1C). To verify the 
efficacy of Flt3L produced, graded doses of CHO/Flt3L 
conditioned medium were used to culture BM for the gen-
eration of DCs in vitro. Higher concentrations of Flt3L in 
BM culture induced DC differentiation more efficiently 
(Fig. 1D). Especially, when the culture media were com-
posed of 10% or higher amount of the Flt3L conditioned 
medium (up to 50%), the increase in number of DCs in 
BM culture became conspicuous (data not shown for BM 
cultures in media with 25% or 50% of the Flt3L con-
ditioned medium). As estimated by Western blot analysis 
above, 10% content of the Flt3L conditioned medium cor-
responds to 1 μg/ml of Flt3L in culture medium. The effi-
cacy to induce DCs in vivo by this Flt3L protein has also 
been demonstrated previously (25,26). 
Candidate miRNAs with potential to regulate DC 
development
To identify miRNAs possibly involved in DC develop-
ment, a Web-based miRNA-target interaction database 
miRWalk2.0 (27), which amalgamates data from a collec-
tion of miRNA-target prediction programs, was used. Ten 
gene targets that are prominent transcription factors known 
to have a pivotal role in DC development – TCF4, Bcl6, 
Irf2, Irf4, Irf8, Id2, SpiB, Batf3, Notch2, Zbtb46 – were 
picked for the prediction software to identify miRNAs that 
possibly regulate these genes by binding to their 3’UTR. 
From the provided list of miRNAs that have a high poten-
tial to bind to the 3’UTR of these transcription factors, 
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Figure 1. Culture of BM cells with CHO/Flt3L-conditioned 
medium produces DCs in vitro. (A) Diagram for the expression 
construct that encodes soluble FLAG and OLLAS tagged mouse 
Flt3L gene with IRES and EGFP (SFO.Flt3L-IRES-EGFP). (B) 
CHO cells stably transfected with SFO.Flt3L-IRES-EGFP 
(CHO/Flt3L cells) were selected and cloned for the high expres-
sion of EGFP. (C) Concentration of mouse Flt3L protein in the 
supernatant from CHO/Flt3L cell culture was titrated using 
anti-OLLAS monoclonal antibody. (D) Time-course quantifi-
cation of CD11c
＋
 DCs per well for each culture condition 
containing 0.1∼10% of Flt3L conditioned medium.
candidate miRNAs were selected dependent upon avail-
ability of detection reagents in our in-house miRNA probe 
collection. Overall, 20 candidate miRNAs were specified 
according to the analyses of 3’UTR sequences from the 
10 transcription factors (Supplemental Fig. 1).
Screening of candidate miRNA expression in DCs 
from BM cultured with Flt3L 
In preliminary efforts to reveal miRNAs that may play a 
role in DC development, expression profiles of the candi-
date miRNAs were assessed in Flt3L culture system of 
mouse BM cells. Using our in-house probe collection, the 
expressions of 20 candidate miRNAs were screened in 
CD11c
＋
 DCs derived from BM culture with Flt3L, which 
were further assorted into B220
−
 cDCs and B220
＋
 pDCs 
(Fig. 2A). Total RNAs isolated from these two subsets of 
cultured DCs were subjected to analysis of miRNA ex-
pression profile by real-time RT-PCR. When the ex-
pression of candidate miRNAs was normalized and their 
relative levels were compared, an exceedingly high ex-
pression of miR-124 was observed in the B220
−
 cDC pop-
ulation from BM culture with Flt3L (Fig. 2B). In the case 
of each individual candidate miRNA profile, all were ex-
pressed more in B220
−
 cDCs than in B220
＋
 pDCs except 
for miR-17 (Fig. 2C). Exceptionally high expression of 
miR-124 in cDCs and its contrasting expression between 
cDCs and pDCs in BM-derived DCs cultured with Flt3L 
suggest that miR-124 may also be differentially expressed 
during ontogeny of DCs in vivo and may play a role in 
their development.
Direct regulation of transcript containing 3’UTR of 
TCF4 by miR-124
According to the analysis of miRNA-target interactions 
above, miR-124 is predicted to bind to the 3’UTR of TCF4 
(Supplemental Fig. 1A). miR-124 is also expected to bind 
to Zbtb46 although the probability is low (i.e., the sum of 
prediction algorithms with significant scores is 1; Supple-
mental Fig. 1J). To see whether miR-124 actually binds 
to these genes and regulates their expression, a dual luci-
ferase reporter assay was performed using a pmirGLO vec-
tor (Fig. 3A). A section, 342 bps, of the 3’UTR of TCF4 
containing the predicted binding site of miR-124 was in-
serted into the multiple cloning site (MCS) of a pmirGLO 
vector (Fig. 3B). A 480 bp section of the 3’UTR of Zbtb46 
was cloned likewise into a pmirGLO vector (Fig. 3C). The 
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Figure 2. Preliminary expression profiles of candidate miRNAs in Flt3L-cultured DC subsets. (A) Gating strategies for pDCs and cDCs 
present in BM culture with Flt3L for 8 days. (B) Normalized expression levels of candidate miRNAs in DC subsets isolated from BM 
culture with Flt3L. (C) Relative expression of individual candidate miRNAs between pDCs and cDCs isolated from BM culture with 
Flt3L.
cloned vectors were co-transfected with miR-124 mimic or 
the negative control into HeLa cells and the luciferase ac-
tivity was measured. The assay showed that the over-
expression of miR-124 was able to down-regulate lucifer-
ase activity of the pmirGLO-TCF4 vector by ∼30% while 
not those of the pmirGLO-control or pmirGLO-Zbtb46 
(Fig. 3D). Besides, the sequences of miR-124 binding site 
found in 3’UTRs of both mouse and human TCF4 tran-
scripts are highly conserved (Fig. 3E). Therefore, it ap-
pears that miR-124 might directly bind to both 3’UTRs of 
mouse and human TCF4 and thus posttranscriptionally reg-
ulate their activity.
Higher expression of miR-124 in cDC1 cells from BM 
culture with Flt3L
TCF4 is a critical transcription factor in the development 
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Figure 3. Regulation of gene expression by miR-124 via direct binding to 3’UTR of target transcript. Diagrams of the luciferase reporter 
vector pmirGLO constructs encoding (A) no insert, i.e., control, or 3’UTR from (B) TCF4 and (C) Zbtb46. (D) Histogram of normalized 
luciferase activities obtained from HeLa cells co-transfected with the respective reporter constructs and miR-124 mimic or negative 
control. Representative results are shown from 3 independent experiments. (E) Predicted binding site of miR-124 in the 3’UTRs of 
mouse and human TCF4.
and homeostasis of pDCs and is expressed at higher levels 
in pDCs and pDC precursors than in other DCs and pro-
genitors (5,28). Therefore, it seems developmentally rele-
vant that lower expression of miR-124 in pDCs than in 
cDCs was observed amongst BM-derived DCs cultured 
with Flt3L in our preliminary screening (Fig. 2). As pre-
viously demonstrated by others (7,29,30), we were able to 
culture BM cells in vitro with Flt3L for 6 to 12 days to 
efficiently produce three major DC subsets that respec-
tively correspond to pDC, cDC1, and cDC2 lineage cells 
in lymphoid tissues in vivo. These DC populations from 
Flt3L-cultured BM were identified and isolated as per their 
surface markers of CD11c
＋
B220
＋
 for pDCs, CD11c
＋
B220
−
CD24
＋
CD172α
−
 for cDC1, and CD11c
＋
B220
−
CD172α
＋
CD24
int
 for cDC2 (Fig. 4A). Then, these three 
DC populations purified from BM culture with Flt3L by 
flow cytometric sorting were subjected to RNA extraction 
and real-time RT-PCR. As mentioned above, the dynamic 
and differential expression of various transcription factors 
across the DC subsets is critical for DC development (10). 
Expressions of TCF4, Batf3, and Irf8 in the DC subsets 
isolated from BM culture with Flt3L (Fig. 4B) were paral-
lel to those previously reported in the DC subsets isolated 
from lymphoid tissues (9), indicating that the isolated DC 
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Figure 4. High expression of miR-124 in cDC1 cells from BM culture with Flt3L. (A) Gating and sorting strategies for pDC, cDC1, and 
cDC2 cells from BM culture with Flt3L. (B) Relative expression of 3 transcription factors critical to DC development is determined 
amongst different DC subsets by real-time RT-PCR. Representative results are shown from 2 independent experiments. (C) Relative 
expression of miR-124 is assessed amongst different DC subsets by real-time RT-PCR. Data from 3 independent experiments are 
presented in histogram. Error bars indicate mean±SEM across all samples from 3 independent experiments. *p≤0.05; **p≤0.01; ***p≤
0.001.
subsets were classified appropriately. Expression of miR- 
124, similar to the results of the preliminary screen (Fig. 2), 
was lower in pDCs than in cDCs, i.e., cDC1 and cDC2 
cells (Fig. 4C). Moreover, cDC1 cells were shown to ex-
press significantly higher levels of miR-124 than both 
pDCs and cDC2 cells.
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Figure 5. Prominent expression 
of miR-124 in cDC1 cells in BM. 
Gating strategies for (A) MDP, 
CDP, (B) pDC, (C) cDC1, and 
cDC2 cells in BM. (D) Relative 
expression of miR-124 is asses-
sed amongst different progenitors 
and DC subsets by real-time RT- 
PCR. Representative results are 
shown from 3 independent ex-
periments. ***p≤0.001.
Expression of miR-124 is higher in cDC1 cells than 
in other DCs, DC precursors, and progenitors in BM 
and spleen
To further verify the expression profiles of miR-124 
amongst DC subsets present in BM culture with Flt3L, we 
examined the expression of miR-124 from DC subsets and 
progenitors present in steady-state BM. MDP, CDP, pDC, 
cDC1, and cDC2 cells present in mouse BM were re-
spectively purified ex vivo by flow cytometric sorting ac-
cording to their surface makers (Fig. 5A-C). When the ex-
tracted RNAs of the respective DC subsets and progenitors 
isolated from BM were analyzed by real-time RT-PCR and 
compared, miR-124 expression was prominently found in 
cDC1 cells at a level much higher than those of MDP, 
CDP, and other DC subsets (Fig. 5D). In addition, we also 
had several BM populations of pre-DCs, including pre- 
cDCs and pre-pDCs (6,7,31), purified and analyzed for 
their expressions of miR-124, which were lower than that 
of cDC1 cells but similar to those of other DC subsets and 
progenitors (data not shown). Therefore, higher expression 
of miR-124 is consistently found in the cDC1 lineage from 
both BM cells and BM-derived cell cultures with Flt3L. 
Then, to observe the patterns of miR-124 expression in 
steady-state spleen, DC subsets and pre-DCs were sorted 
ex vivo from freshly prepared splenocytes according to 
their surface makers (Fig. 6A-C). Real-time RT-PCR of 
the extracted RNA from the sorted splenic cells also re-
vealed a relatively high expression of miR-124 in cDC1 
cells compared to other DC subsets and pre-DCs in spleen 
(Fig. 6D), therefore suggesting that the abundant expres-
sion of miR-124 might be important to the development 
of all cDC1 lineage cells in general. 
All three miR-124 precursor transcripts contribute to 
miR-124 expression in cDC1 cells
As depicted in Fig. 7A, there are three primary miRNA 
genes for miR-124: pri-miR-124-1, pri-miR-124-2, and 
pri-miR-124-3 (32,33). Three transcripts originate from 
these three different genes on separate chromosomes but 
all convert into the same mature miR-124 sequence. With 
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Figure 6. Elevated expression of 
miR-124 in cDC1 cells in spleen. 
Gating strategies for (A) pre-DC, 
(B) pDC, (C) cDC1, and cDC2 
cells in spleen. (D) Relative ex-
pression of miR-124 is evaluated 
amongst different DC precursor 
and subsets by real-time RT-PCR. 
Representative results are shown 
from 3 independent experiments. 
***p≤0.001.
oligonucleotide probes to distinguish and detect the three 
pri-miR-124 transcripts (24), real-time RT-PCR was per-
formed to determine which miR-124 precursors were ex-
pressed more in the cDC1 lineage. Expression profiling of 
pri-miR-124 in the cDC1 cells from steady-state BM (Fig. 
7B) and spleen (Fig. 7C) showed similar patterns of miR- 
124 precursor expression. In both tissues, cDC1 cells showed 
that pri-miR-124-1 was expressed the least and pri-miR- 
124-3 was expressed the most but all three precursors were 
expressed within the ranges of no significant statistical 
difference. In addition, expression of the three pri-miR-124 
genes was measured in other DC subsets where transcripts 
of all three precursor genes were also detected sig-
nificantly (data not shown). In other words, the definitive 
expression of all three pri-miR-124 transcripts indicates 
that they all contribute significantly to the generation of 
mature miR-124 in cDC1 lineage cells.
DISCUSSION
MicroRNA-124 is known as the most abundant microRNA 
expressed in neuronal cells (34,35). Although many miRNAs 
are starting to be linked to immunological processes, miR- 
124 remains unmentioned. Therefore, our finding of the out-
standing and differential expression of miR-124 in BM-de-
rived DCs cultured with Flt3L is intriguing as they are paral-
leled with DC development in vivo. Since homeostasis of 
DCs in vivo is critically dependent on Flt3L, we aimed to 
critically define the dynamic profile of miR-124 in the DC 
subpopulations and delineate its interplay with relevant tran-
scription factors that influence the development and function 
of particular DC subsets. Analyzing the prediction algorithm 
software, TCF4 was shown to be a probable target of 
miR-124 while Zbtb46 was shown to be a less likely target. 
Although it would be important to show the levels of TCF4 
or Zbtb46 proteins following treatment with miR-124 mimic 
in naturally TCF4- or Zbtb46-expressing cells, we could 
not carry out those experiments in such cells as pDCs and 
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Figure 7. All three primary miR- 
124 genes are actively transcri-
bed in DCs. (A) Genomic map of 
three pri-miR-124 genes on three 
different chromosomal locations 
are illustrated with their seque-
nce information of GenBank 
accession numbers. (B) Relative 
expression of three pri-miR-124 
genes is determined from cDC1 
cells in BM by real-time RT- 
PCR. Results combined from 2 
independent experiments are 
shown. (C) Relative expression 
of three pri-miR-124 genes is 
assessed from cDC1 cells in 
spleen by real-time RT-PCR. 
pre-DCs but performed dual luciferase assays in HeLa cells 
instead. Symmetrical to the prediction software, the lucifer-
ase activity assay showed that miR-124 mimic can bind 
and regulate the transcript carrying a 3’UTR section of 
TCF4.
  Since TCF4 has been established to be a critical gene 
in the development and homeostasis of pDCs, this data 
suggested that miR-124 may play a role in this process. 
This led us to hypothesize that miR-124 would be least 
expressed in pDCs, as its high expression would more ef-
fectively target TCF4 mRNA for degradation and thus in-
hibit pDC development and function. The miR-124 ex-
pression profiles of Flt3L-cultured DC subsets correlated 
with this hypothesis so that miR-124 was least expressed 
in the pDC subset. Further expression profiling in steady- 
state BM and spleen, however, showed that miR-124 ex-
pression was conspicuously higher only in the cDC1 line-
age but lower in both pDCs and cDC2 cells as well as 
in precursors and progenitors. This hints that miR-124, like 
most other miRNAs, does not act on DC development 
one-dimensionally through single miRNA to single tar-
get/transcription factor mechanism, but instead acts through 
single miRNA to multiple targets/transcription factors me-
chanism. Therefore, we speculate that the differential ex-
pression of miR-124 in different subsets may influence DC 
development broadly and profoundly. 
  Vital role of several miRNAs in development of specific 
DC subsets has been characterized in the mice genetically 
deficient of such miRNA genes (16,19). Unlike those 
miRNAs, miR-124 has three precursor genes. Moreover, 
all three pri-miR-124 genes located on different chromo-
somes appear to significantly contribute to the expression 
of mature miR-124 in DC subsets. It would be quite diffi-
cult and unlikely that the triple knockout mice deficient 
of all three pri-miR-124 genes become available in the 
near future. Therefore, it is not currently possible to dem-
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onstrate the in vivo role of miR-124. Although the effect 
is transient and limited, transfection of its mimicking or 
inhibiting molecules into DC precursors and progenitors 
followed by culture with Flt3L will be able to validate the 
role of miR-124. All in all, the dynamic profiles of miR- 
124 expression are consistent within the in vitro-generated 
DC subsets and their in situ counterparts in lymphoid 
tissues. Highly dynamic activity of miR-124 during DC 
development requires elucidation of its purpose for such 
fluctuation.
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4985bp 
A 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRDB miRWalk miRanda Targetscan SUM 
Tcf4 mmu-miR-155 mmu-mir-155 UUAAUGCUAAUUGUGAUAGGGGU  1 1 1 1 4 
Tcf4 mmu-miR-29b mmu-mir-29b-2 CUGGUUUCACAUGGUGGCUUAGAUU  0 1 1 1 3 
Tcf4 mmu-miR-101a mmu-mir-101a UACAGUACUGUGAUAACUGAA  0 1 1 1 3 
Tcf4 mmu-miR-26b mmu-mir-26b UUCAAGUAAUUCAGGAUAGGU  0 1 1 1 3 
Tcf4 mmu-miR-181d mmu-mir-181d AACAUUCAUUGUUGUCGGUGGGU  0 1 1 1 3 
Tcf4 mmu-miR-130b mmu-mir-130b CAGUGCAAUGAUGAAAGGGCAU  0 1 1 1 3 
Tcf4 mmu-miR-181c mmu-mir-181c AACAUUCAACCUGUCGGUGAGU  0 1 1 1 3 
Tcf4 mmu-miR-29c mmu-mir-29c UAGCACCAUUUGAAAUCGGUUA  0 1 1 1 3 
Tcf4 mmu-miR-181a mmu-mir-181a-1 AACAUUCAACGCUGUCGGUGAGU  0 1 1 1 3 
Tcf4 mmu-miR-124 mmu-mir-124-2 UAAGGCACGCGGUGAAUGCC  0 1 1 1 3 
Tcf4 mmu-miR-92b mmu-mir-92b UAUUGCACUCGUCCCGGCCUCC  0 1 1 1 3 
Tcf4 mmu-miR-145 mmu-mir-145 GUCCAGUUUUCCCAGGAAUCCCU  0 1 1 1 3 
Tcf4 mmu-miR-1-2-as mmu-mir-1-2-as UACAUACUUCUUUACAUUCCA  0 1 1 1 3 
Tcf4 mmu-miR-101b mmu-mir-101b GUACAGUACUGUGAUAGCU  0 1 1 1 3 
Tcf4 mmu-miR-146b mmu-mir-146b UGAGAACUGAAUUCCAUAGGCU  0 1 1 1 3 
Mouse TCF4 - 3’UTR 
Mouse Bcl6 - 3’UTR 
PITA and RNA22 omitted because TCF4 not registered. 
Only binding sites of miRNA with SUM ≥ 3 shown. 
1073bp 
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mmu-miR-142-5p 
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mmu-miR-17 
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Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRanda miRDB miRWalk PITA RNA22 Targetscan SUM 
Bcl6 mmu-miR-9 mmu-mir-9-1 UCUUUGGUUAUCUAGCUGUAUGA 1 1 1 1 1 1 6 
Bcl6 mmu-miR-17 mmu-mir-17 CAAAGUGCUUACAGUGCAGGUAG  0 0 1 1 1 1 4 
Bcl6 mmu-miR-181a mmu-mir-181a-1 AACAUUCAACGCUGUCGGUGAGU 0 0 1 1 1 1 4 
Bcl6 mmu-miR-181b mmu-mir-181b-1 AACAUUCAUUGCUGUCGGUGGGU  0 0 1 1 1 1 4 
Bcl6 mmu-miR-181c mmu-mir-181c AACAUUCAACCUGUCGGUGAGU  0 0 1 1 1 1 4 
Bcl6 mmu-miR-181d mmu-mir-181d AACAUUCAUUGUUGUCGGUGGGU 0 0 1 1 1 1 4 
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Bcl6 mmu-miR-26b mmu-mir-26b UUCAAGUAAUUCAGGAUAGGU  0 0 1 1 0 1 3 
Only binding sites of miRNA with SUM ≥ 3 shown. 
B 
Supplemental Figure 1 
Mouse Irf4 - 3’UTR 
3260bp 
0kb 1kb 2kb 
mmu-miR-125a-5p 
mmu-miR-1-2-as 
3kb 
mmu-miR-125a-5p 
mmu-miR-9 
mmu-miR-101a 
mmu-let-7b 
mmu-miR-23a/b 
mmu-miR-17 
mmu-miR-92b 
mmu-miR-130b 
mmu-miR-125a-3p 
mmu-miR-181a/b/c/d 
mmu-miR-23a/b 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRWalk miRanda miRDB PITA RNA22 Targetscan SUM 
Irf4 mmu-miR-125a-5p mmu-mir-125a UCCCUGAGACCCUUUAACCUGUGA 1 1 1 1 1 1 6 
Irf4 mmu-miR-181c mmu-mir-181c AACAUUCAACCUGUCGGUGAGU 1 1 0 1 1 1 5 
Irf4 mmu-miR-1-2-as mmu-mir-1-2-as UACAUACUUCUUUACAUUCCA 1 1 1 0 1 1 5 
Irf4 mmu-miR-181d mmu-mir-181d AACAUUCAUUGUUGUCGGUGGGU  1 1 0 1 1 1 5 
Irf4 mmu-miR-23a mmu-mir-23a AUCACAUUGCCAGGGAUUUCC  1 1 0 1 1 1 5 
Irf4 mmu-miR-92b mmu-mir-92b UAUUGCACUCGUCCCGGCCUCC  1 1 0 1 1 1 5 
Irf4 mmu-miR-23b mmu-mir-23b AUCACAUUGCCAGGGAUUACC  1 1 0 1 1 1 5 
Irf4 mmu-miR-181a mmu-mir-181a-1 AACAUUCAACGCUGUCGGUGAGU 1 1 0 1 1 1 5 
Irf4 mmu-miR-130b mmu-mir-130b CAGUGCAAUGAUGAAAGGGCAU  1 1 0 1 1 1 5 
Irf4 mmu-miR-181b mmu-mir-181b-1 AACAUUCAUUGCUGUCGGUGGGU 1 1 0 1 1 1 5 
Irf4 mmu-miR-17 mmu-mir-17 CAAAGUGCUUACAGUGCAGGUAG  1 0 0 1 1 1 4 
Irf4 mmu-miR-101a mmu-mir-101a UACAGUACUGUGAUAACUGAA  1 1 0 0 1 1 4 
Irf4 mmu-let-7b mmu-let-7b UGAGGUAGUAGGUUGUGUGGUU  1 0 0 1 1 1 4 
Irf4 mmu-miR-9 mmu-mir-9-1 UCUUUGGUUAUCUAGCUGUAUGA  1 0 0 1 1 1 4 
Irf4 mmu-miR-146a mmu-mir-146a UGAGAACUGAAUUCCAUGGGUU 1 0 0 1 1 0 3 
Irf4 mmu-miR-125a-3p mmu-mir-125a ACAGGUGAGGUUCUUGGGAGCC 0 0 0 1 1 1 3 
Irf4 mmu-miR-146b mmu-mir-146b UGAGAACUGAAUUCCAUAGGCU  1 0 0 1 1 0 3 
Only binding sites of miRNA with SUM ≥ 3 shown. 
Shaded area indicates overlapping binding sites of two distinct miRNAs 
D 
C 
Mouse Irf2 - 3’UTR 
1236bp 
0.25kb 0.5kb 0.75kb 
mmu-miR-133a mmu-miR-221 
0kb 1kb 
mmu-miR-23a/b 
mmu-miR-15a/b 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRWalk miRanda miRDB PITA RNA22 Targetscan SUM 
Irf2 mmu-miR-23a mmu-mir-23a AUCACAUUGCCAGGGAUUUCC  1 1 1 1 0 1 5 
Irf2 mmu-miR-23b mmu-mir-23b AUCACAUUGCCAGGGAUUACC  1 1 1 1 0 1 5 
Irf2 mmu-miR-221 mmu-mir-221 AGCUACAUUGUCUGCUGGGUUUC  1 1 1 1 0 1 5 
Irf2 mmu-miR-133a mmu-mir-133a-2 UUUGGUCCCCUUCAACCAGCUG  1 1 0 1 0 1 4 
Irf2 mmu-miR-15a mmu-miR-15a UAGCAGCACAUAAUGGUUUGUG 1 0 0 1 1 0 3 
Irf2 mmu-miR-15b mmu-miR-15b UAGCAGCACAUCAUGGUUUACA 1 0 0 1 1 0 3 
Only binding sites of miRNA with SUM ≥ 3 shown 
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Mouse Irf8 - 3’UTR 
1517bp 
0.5kb 1kb 1.5kb 
mmu-miR-181a/b mmu-miR-17 
0kb 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRWalk miRanda miRDB PITA RNA22 Targetscan SUM 
Irf8 mmu-miR-17 mmu-mir-17 CAAAGUGCUUACAGUGCAGGUAG 1 1 0 0 1 1 4 
Irf8 mmu-miR-181b mmu-mir-181b-2 AACAUUCAUUGCUGUCGGUGGGU 1 1 0 0 1 1 4 
Irf8 mmu-miR-181a mmu-mir-181a-1 AACAUUCAACGCUGUCGGUGAGU 1 1 0 0 0 1 3 
Only binding sites of miRNA with SUM ≥ 3 shown 
F 
E 
G 
Mouse SpiB - 3’UTR 
0.5kb 0kb 1kb 1.5kb 
1964bp 
mmu-miR-125a-5p 
mmu-miR-221 
mmu-miR-146a/b 
mmu-miR-124 
mmu-miR-221 
mmu-miR-125-3p 
mmu-miR-140 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRWalk miRanda miRDB PITA RNA22 Targetscan SUM 
Spib mmu-miR-221 mmu-mir-221 AGCUACAUUGUCUGCUGGGUUUC  1 1 0 1 1 1 5 
Spib mmu-miR-146b mmu-mir-146b UGAGAACUGAAUUCCAUAGGCU  1 1 0 1 0 1 4 
Spib mmu-miR-146a mmu-mir-146a UGAGAACUGAAUUCCAUGGGUU  1 1 0 1 0 1 4 
Spib mmu-miR-124 mmu-mir-124-2 UAAGGCACGCGGUGAAUGCC  1 1 0 1 0 1 4 
Spib mmu-miR-140 mmu-mir-140 CAGUGGUUUUACCCUAUGGUAG 0 0 0 1 1 1 3 
Spib mmu-miR-125a-3p mmu-mir-125a ACAGGUGAGGUUCUUGGGAGCC  1 0 0 1 1 0 3 
Spib mmu-miR-125a-5p mmu-mir-125a UCCCUGAGACCCUUUAACCUGUGA 1 0 0 1 1 0 3 
Only binding sites of miRNA with SUM ≥ 3 shown 
Mouse Id2 - 3’UTR 
785bp 
0.25kb 0.5kb 0.75kb 
mmu-miR-142-5p mmu-miR-181a/b/c/d 
0kb 
mmu-miR-155 
Only binding sites of miRNA with SUM ≥ 3 shown 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRWalk miRanda miRDB PITA RNA22 Targetscan SUM 
Id2 mmu-miR-181a mmu-mir-181a-1 AACAUUCAACGCUGUCGGUGAGU 1 1 0 1 1 1 5 
Id2 mmu-miR-181d mmu-mir-181d AACAUUCAUUGUUGUCGGUGGGU 1 1 0 1 1 1 5 
Id2 mmu-miR-181b mmu-mir-181b-2 AACAUUCAUUGCUGUCGGUGGGU  1 1 0 1 0 1 4 
Id2 mmu-miR-181c mmu-mir-181c AACAUUCAACCUGUCGGUGAGU  1 1 1 0 0 1 4 
Id2 mmu-miR-142-5p mmu-mir-142 CAUAAAGUAGAAAGCACUACU 0 0 0 1 1 1 3 
Id2 mmu-miR-155 mmu-mir-155 UUAAUGCUAAUUGUGAUAGGGGU  1 0 0 1 0 1 3 
Supplemental Figure 1 
Mouse Batf3 - 3’UTR 
310bp 
0.1kb 0.2kb 0.3kb 
mmu-miR-125a-3p mmu-miR-17 
0kb 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRWalk miRanda miRDB PITA RNA22 Targetscan SUM 
Batf3 mmu-miR-125a-3p mmu-mir-125a ACAGGUGAGGUUCUUGGGAGCC  1 1 0 1 1 0 4 
Batf3 mmu-miR-17 mmu-mir-17 CAAAGUGCUUACAGUGCAGGUAG  1 1 0 1 1 0 4 
Only binding sites of miRNA with SUM ≥ 3 shown 
H 
I 
Mouse Notch2 - 3’UTR 
2923bp 
1kb 2kb 
mmu-miR-1 
mmu-miR-29b/c 
0kb 
mmu-miR-125-5p 
mmu-miR-101a 
mmu-miR-21 
mmu-miR-125a-3p 
mmu-miR-17 
mmu-miR-146a/b 
mmu-let-7 
mmu-miR-142-5p 
mmu-miR-23a/b 
mmu-miR-26a/b 
mmu-miR-9 
mmu-miR-132 
mmu-miR-181a/b/c/d 
Only binding sites of miRNA with SUM ≥ 3 shown 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRWalk miRanda miRDB PITA RNA22 
Target 
scan 
SUM 
Notch2 mmu-miR-9 mmu-mir-9-1 UCUUUGGUUAUCUAGCUGUAUGA 1 1 1 1 1 1 6 
Notch2 mmu-miR-181c mmu-mir-181c AACAUUCAACCUGUCGGUGAGU  1 1 0 1 1 1 5 
Notch2 mmu-miR-181a mmu-mir-181a-1 AACAUUCAACGCUGUCGGUGAGU 1 1 0 1 1 1 5 
Notch2 mmu-miR-21 mmu-mir-21a UAGCUUAUCAGACUGAUGUUGA 1 1 0 1 1 1 5 
Notch2 mmu-miR-142-5p mmu-mir-142 CAUAAAGUAGAAAGCACUACU 1 1 0 1 1 1 5 
Notch2 mmu-miR-125a-3p mmu-mir-125a ACAGGUGAGGUUCUUGGGAGCC 1 1 0 1 1 1 5 
Notch2 mmu-let-7e mmu-let-7e UGAGGUAGGAGGUUGUAUAGUU 1 0 0 1 1 1 4 
Notch2 mmu-miR-101a mmu-mir-101a UACAGUACUGUGAUAACUGAA  1 1 0 1 0 1 4 
Notch2 mmu-let-7a mmu-let-7a-1 UGAGGUAGUAGGUUGUAUAGUU 1 0 0 1 1 1 4 
Notch2 mmu-miR-132 mmu-mir-132 UAACAGUCUACAGCCAUGGUCG 1 1 0 1 0 1 4 
Notch2 mmu-let-7f mmu-let-7f-1 UGAGGUAGUAGAUUGUAUAGUU 1 0 0 1 1 1 4 
Notch2 mmu-miR-1 mmu-mir-1a-1 UGGAAUGUAAAGAAGUAUGUAU 1 1 0 1 0 1 4 
Notch2 mmu-let-7b mmu-let-7b UGAGGUAGUAGGUUGUGUGGUU  1 0 0 1 1 1 4 
Notch2 mmu-miR-26a mmu-mir-26a-1 UUCAAGUAAUCCAGGAUAGGCU 1 0 0 1 1 1 4 
Notch2 mmu-let-7g mmu-let-7g UGAGGUAGUAGUUUGUACAGUU 1 0 0 1 1 1 4 
Notch2 mmu-miR-146a mmu-mir-146a UGAGAACUGAAUUCCAUGGGUU  1 0 0 1 1 1 4 
Notch2 mmu-let-7c mmu-let-7c UGAGGUAGUAGGUUGUAUGGUU 1 0 0 1 1 1 4 
Notch2 mmu-miR-181b mmu-mir-181b-1 AACAUUCAUUGCUGUCGGUGGGU  0 1 0 1 1 1 4 
Notch2 mmu-let-7i mmu-let-7i UGAGGUAGUAGUUUGUGCUGUU 1 0 0 1 1 1 4 
Notch2 mmu-let-7d mmu-let-7d CUAUACGACCUGCUGCCUUUCU 0 0 0 1 1 1 3 
Notch2 mmu-miR-181d mmu-mir-181d AACAUUCAUUGUUGUCGGUGGGU 0 1 0 1 0 1 3 
Notch2 mmu-miR-17 mmu-mir-17 CAAAGUGCUUACAGUGCAGGUAG  1 0 0 1 1 0 3 
Notch2 mmu-miR-23a mmu-mir-23a AUCACAUUGCCAGGGAUUUCC  0 0 0 1 1 1 3 
Notch2 mmu-miR-29b mmu-mir-29b-2 CUGGUUUCACAUGGUGGCUUAGAUU  1 0 0 1 1 0 3 
Notch2 mmu-miR-23b mmu-mir-23b AUCACAUUGCCAGGGAUUACC  0 0 0 1 1 1 3 
Notch2 mmu-miR-26b mmu-mir-26b UUCAAGUAAUUCAGGAUAGGU  1 0 0 1 0 1 3 
Notch2 mmu-miR-29c mmu-mir-29c UAGCACCAUUUGAAAUCGGUUA  1 0 0 1 1 0 3 
Notch2 mmu-miR-146b mmu-mir-146b UGAGAACUGAAUUCCAUAGGCU  1 0 0 1 0 1 3 
Notch2 mmu-miR-125a-5p mmu-mir-125a UCCCUGAGACCCUUUAACCUGUGA 1 0 0 1 1 0 3 
Supplemental Figure 1 
J 
Mouse Zbtb46 - 3’UTR 
Gene MicroRNA StemLoop ID Sequence (5’  3’)  miRWalk miRanda miRDB RNA22 Targetscan SUM 
Zbtb46 mmu-miR-9 mmu-mir-9-1 UCUUUGGUUAUCUAGCUGUAUGA 1 1 0 1 1 4 
Zbtb46 mmu-miR-1-2-as mmu-mir-1-2-as UACAUACUUCUUUACAUUCCA 1 1 0 1 1 4 
Zbtb46 mmu-miR-133b mmu-mir-133b UUUGGUCCCCUUCAACCAGCUA 1 0 0 1 1 3 
Zbtb46 mmu-miR-15a mmu-miR-15a UAGCAGCACAUAAUGGUUUGUG 1 0 0 1 1 3 
Zbtb46 mmu-miR-15b mmu-miR-15b UAGCAGCACAUCAUGGUUUACA 1 0 0 1 1 3 
Zbtb46 mmu-miR-133a mmu-mir-133a-2 UUUGGUCCCCUUCAACCAGCUG  1 0 0 1 1 3 
PITA omitted because Zbtb46 not registered 
Only binding sites of miRNA with SUM ≥ 3 shown  
Shaded area indicates overlapping binding sites of two distinct miRNAs 
*mmu-miR-124 not in chart because SUM = 1 
3064bp 
0.5kb 2.5kb 0kb 
mmu-miR-15a/b 
mmu-miR-1-2-as 
1kb 1.5kb 2kb 
mmu-miR-9 
mmu-miR-133a/b 
3kb 
*mmu-miR-124 
Supplemental Figure 1 
Supplemental Figure 1. Identification of candidate miRNAs that potentially 
target the transcript of transcription factors in DC development.  miRWalk2.0 
was used to identify miRNAs with high probability to bind to the 3’UTR of the listed 
transcription factors.  miRanda, miRWalk, miRDB, PITA, RNA22, and TargetScan 
prediction algorithms were used and miRNAs with significant scores from at least 3 
of the algorithms were listed (SUM ≥ 3).  (A) Candidate list of miRNAs that target 
TCF4 and the map of 3’UTR diagram for TCF4 with the predicted binding sites of 
the candidates.  The same is shown for (B) Bcl6, (C) Irf2, (D) Irf4, (E) Irf8, (F) Id2, 
(G) SpiB, (H) Batf3, (I) Notch2, and (J) Zbtb46. 
